ABIONYX Pharma S.A.
ABNX.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$65.13M
Close$
Share Statistics
| Market cap | $65.13 Million |
|---|---|
| Enterprise Value | $54.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.16 |
| Beta | 0.48 |
| Outstanding Shares | 35,979,484 |
Return
| Return on Equity | -80.68% |
|---|---|
| Return on Assets | -34.63% |
| Return on Invested Capital | -36.21% |
Valuation & Multiples
| P/E Ratio | -6.97 |
|---|---|
| PEG | -6.38 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.56 |
| Enterprise Value to EBIT | -4.87 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 1.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.90 M
Average shareholder expectationNext Earnings Call
Expected Date
March 16, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.11 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ABIONYX Pharma S.A.
49 employees
CEO: Sir Cyrille Tupin ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein p...